Advertisement

Archives of Virology

, Volume 163, Issue 6, pp 1649–1655 | Cite as

Inhibitory effect of the green tea molecule EGCG against dengue virus infection

  • Muhareva Raekiansyah
  • Corazon C. Buerano
  • Mark Anthony D. Luz
  • Kouichi Morita
Brief Report

Abstract

Dengue virus (DENV) infection is a major public health problem worldwide; however, specific antiviral drugs against it are not available. Hence, identifying effective antiviral agents for the prevention of DENV infection is important. In this study, we showed that the reportedly highly biologically active green-tea component epigallocatechin gallate (EGCG) inhibited dengue virus infection regardless of infecting serotype, but no or minimal inhibition was observed with other flaviviruses, including Japanese encephalitis virus, yellow fever virus, and Zika virus. EGCG exerted its antiviral effect mainly at the early stage of infection, probably by interacting directly with virions to prevent virus infection. Our results suggest that EGCG specifically targets DENV and might be used as a lead structure to develop an antiviral drug for use against the virus.

Notes

Acknowledgements

The authors are grateful to members of the Department of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan, for their support. This research was supported by the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) of Japan Agency for Medical Research and Development (AMED).

Compliance with ethical standards

Ethical approval

This article does not contain any studies with animals performed by any of the authors.

Conflict of interest

The authors declare that no conflict of interest exists.

Supplementary material

705_2018_3769_MOESM1_ESM.docx (245 kb)
Supplementary material 1 (DOCX 244 kb)

References

  1. 1.
    Adungo F, Yu F, Kamau D, Inoue S, Hayasaka D, Posadas-Herrera G, Sang R, Mwau M, Morita K (2016) Development and characterization of monoclonal antibodies to yellow fever virus and application in antigen detection and IgM capture enzyme-linked immunosorbent assay. Clin Vaccine Immunol 23(8):689–697CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Calland N, Sahuc ME, Belouzard S, Pène V, Bonnafous P, Mesalam AA, Deloison G, Descamps V, Sahpaz S, Wychowski C, Lambert O, Brodin P, Duverlie G, Meuleman P, Rosenberg AR, Dubuisson J, Rouillé Y, Séron K (2015) Polyphenols inhibit hepatitis C virus entry by a new mechanism of action. J Virol 89(19):10053–10063CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Carneiro BM, Batista MN, Braga ACS, Nogueira ML, Rahal P (2016) The green tea molecule EGCG inhibits Zika virus entry. Virology 496:215–218CrossRefPubMedGoogle Scholar
  4. 4.
    Cazarolli LH, Zanatta L, Alberton EH, Figueiredo MS, Folador P, Damazio RG, Pizzolatti MG, Silva FR (2008) Flavonoids: prospective drug candidates. Mini Rev Med Chem 8(13):1429–1440CrossRefPubMedGoogle Scholar
  5. 5.
    Chow H, Cai Y, Alberts DS, Hakim I, Dorr R, Shahi F, Crowell JA, Yang CS, Hara Y (2003) Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9(9):3312–3319PubMedGoogle Scholar
  6. 6.
    Clark J, You M (2006) Chemoprevention of lung cancer by tea. Mol Nutr Food Res 50:144–151CrossRefPubMedGoogle Scholar
  7. 7.
    Colpitts CC, Schang LM (2014) A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans. J Virol 88(14):7806–7817CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Halstead SB (2007) Dengue. Lancet 370:1644–1652CrossRefPubMedGoogle Scholar
  9. 9.
    Isaacs CE, Wen GY, Xu W, Jia JH, Rohan L, Corbo C (2008) Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrob Agents Chemother 52:962–970CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ismail NA, Jusoh SA (2017) Molecular docking and molecular dynamics simulation studies to predict flavonoid binding on the surface of DENV2 E protein. Interdiscip Sci 9(4):499–511CrossRefPubMedGoogle Scholar
  11. 11.
    Kim M, Kim SY, Lee HW, Shin JS, Kim P, Jung YS, Jeong HS, Hyun JK, Lee CK (2013) Inhibition of influenza virus internalization by (-)-epigallocatechin-3-gallate. Antivir Res 100(2):460–472CrossRefPubMedGoogle Scholar
  12. 12.
    Kinghorn AD, Pan L, Fletcher JN, Chai H (2011) The relevance of higher plants in lead compound discovery programs. J Nat Prod 74:1539–1555CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Liu G, Xiong S, Xiang YF, Guo CW, Ge F, Yang CR, Zhang YJ, Wang YF, Kitazato K (2011) Antiviral activity and possible mechanisms of action of pentagalloylglucose (PGG) against influenza A virus. Arch Virol 156(8):1359–1369CrossRefPubMedGoogle Scholar
  14. 14.
    Lu JW, Hsieh PS, Lin CC, Hu MK, Huang SM, Wang YM, Liang CY, Gong Z, Ho YJ (2017) Synergistic effects of combination treatment using EGCG and suramin against the chikungunya virus. Biochem Biophys Res Commun 491(3):595–602CrossRefPubMedGoogle Scholar
  15. 15.
    Lipson SM, Karalis G, Karthikeyan L, Ozen FS, Gordon RE, Ponnala S, Bao J, Samarrai W, Wolfe E (2017) Mechanism of anti-rotavirus synergistic activity by epigallocatechin gallate and a proanthocyanidin-containing nutraceutical. Food Environ Virol 4:434–443CrossRefGoogle Scholar
  16. 16.
    Munin A, Edwards-Lévy F (2011) Encapsulation of natural polyphenolic compounds; a review. Pharmaceutics 3(4):793–829CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    O’Shea D, Law J, Egli A, Douglas D, Lund G, Forester S, Lambert J, Law M, Burton DR, Tyrrell DL, Houghton M, Humar A, Kneteman N (2016) Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. Liver Transpl 22(3):324–332CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Raekiansyah M, Mori M, Nonaka K, Agoh M, Shiomi K, Matsumoto A, Morita K (2017) Identification of novel antiviral of fungus-derived brefeldin A against dengue viruses. Trop Med Health 45(32):1–7Google Scholar
  19. 19.
    Raekiansyah M, Espada-Murao LA, Okamoto K, Kubo T, Morita K (2014) Dengue virus neither directly mediates hyperpermeability nor enhances tumor necrosis factor-α-induced permeability in vitro. Jpn J Infect Dis 67(2):86–94CrossRefPubMedGoogle Scholar
  20. 20.
    Steinmann J, Buer J, Pietschmann T, Steinmann E (2013) Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol 168:1059–1073CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sullivan NJ (2001) Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol 260:145–169PubMedGoogle Scholar
  22. 22.
    Uchida L, Espada-Murao LA, Takamatsu Y, Okamoto K, Hayasaka D, Yu F, Nabeshima T, Buerano CC, Morita K (2014) The dengue virus conceals double-stranded RNA in the intracellular membrane to escape from an interferon response. Sci Rep 4:7395CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Vázquez-Calvo Á, Jiménez de Oya N, Martín-Acebes MA, Garcia-Moruno E, Saiz JC (2017) Antiviral properties of the natural polyphenols delphinidin and epigallocatechin gallate against the flaviviruses West Nile virus, Zika virus, and dengue virus. Front Microbiol 8:1314CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Weber C, Sliva K, von Rhein C, Kümmerer BM, Schnierle BS (2015) The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Antivir Res 113:1–3CrossRefPubMedGoogle Scholar
  25. 25.
    Yamaguchi K, Honda M, Ikigai H, Hara Y, Shimamura T (2002) Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antivir Res 53(1):19–34CrossRefPubMedGoogle Scholar
  26. 26.
    Yamauchi R, Sasaki K, Yoshida K (2009) Identification of epigallocatechin-3-gallate in green tea polyphenols as a potent inducer of p53-dependent apoptosis in the human lung cancer cell line A549. Toxicol In Vitro 23(5):834–839CrossRefPubMedGoogle Scholar
  27. 27.
    Zandi K, Teoh BT, Sam SS, Wong PF, Mustafa MR, Abubakar S (2012) Novel antiviral activity of baicalein against dengue virus. BMC Complement Altern Med 12:214CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Muhareva Raekiansyah
    • 1
  • Corazon C. Buerano
    • 1
    • 2
  • Mark Anthony D. Luz
    • 1
  • Kouichi Morita
    • 1
  1. 1.Department of Virology, Institute of Tropical MedicineNagasaki UniversityNagasakiJapan
  2. 2.Research and Biotechnology, St. Luke’s Medical CenterQuezon CityPhilippines

Personalised recommendations